Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer

Amit M. Algotar, M. Suzanne Stratton, Frederick R Ahmann, James Ranger-Moore, Raymond B Nagle, Patricia A. Thompson, Elizabeth Slate, Chiu-Hsieh Hsu, Bruce L. Dalkin, Puneet Sindhwani, Michael A. Holmes, John A. Tuckey, David L. Graham, Howard L. Parnes, Lawrence C. Clark, Steven P Stratton

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Purpose This study was conducted to investigate the effect of Se supplementation on prostate cancer incidence in men at high risk for prostate cancer. Methods A Phase 3 randomized, double-blind, placebo-controlled clinical trial was conducted in 699 men at high risk for prostate cancer (prostate specific antigen (PSA) >4 ng/ml and/or suspicious digital rectal examination and/or PSA velocity >0.75 ng/ml/year), but with a negative prostate biopsy. Participants were randomized to receive daily oral placebo (N = 232), 200 μg selenium (N = 234), or 400 μg selenium (N = 233) as selenized yeast. They were followed every 6 months for up to 5 years. The time to diagnosis of prostate cancer was compared between treatment groups using the Cox proportional hazards model. Result Compared to placebo, the hazard ratios [95% confidence intervals] for risk of developing prostate cancer in the selenium 200 μg/day or the selenium 400 μg/day group were 0.94 [0.52, 1.7] and 0.90 [0.48, 1.7], respectively. PSA velocity in the selenium arms was not significantly different from that observed in the placebo group (P = 0.18 and P = 0.17, respectively). Conclusion Selenium supplementation appeared to have no effect on the incidence of prostate cancer in men at high risk. In conjunction with Results of other studies, these data indicate that selenium supplementation may not have a role in prostate cancer chemoprevention. Prostate 73: 328-335, 2013. © 2012 Wiley Periodicals, Inc.

Original languageEnglish (US)
Pages (from-to)328-335
Number of pages8
JournalProstate
Volume73
Issue number3
DOIs
StatePublished - Feb 15 2013

Fingerprint

Phase III Clinical Trials
Selenium
Prostatic Neoplasms
Prostate-Specific Antigen
Placebos
Prostate
Digital Rectal Examination
Incidence
Controlled Clinical Trials
Chemoprevention
Proportional Hazards Models
Yeasts
Confidence Intervals
Biopsy

Keywords

  • incidence
  • prostate cancer
  • selenium supplementation

ASJC Scopus subject areas

  • Urology
  • Oncology

Cite this

Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. / Algotar, Amit M.; Stratton, M. Suzanne; Ahmann, Frederick R; Ranger-Moore, James; Nagle, Raymond B; Thompson, Patricia A.; Slate, Elizabeth; Hsu, Chiu-Hsieh; Dalkin, Bruce L.; Sindhwani, Puneet; Holmes, Michael A.; Tuckey, John A.; Graham, David L.; Parnes, Howard L.; Clark, Lawrence C.; Stratton, Steven P.

In: Prostate, Vol. 73, No. 3, 15.02.2013, p. 328-335.

Research output: Contribution to journalArticle

Algotar, AM, Stratton, MS, Ahmann, FR, Ranger-Moore, J, Nagle, RB, Thompson, PA, Slate, E, Hsu, C-H, Dalkin, BL, Sindhwani, P, Holmes, MA, Tuckey, JA, Graham, DL, Parnes, HL, Clark, LC & Stratton, SP 2013, 'Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer', Prostate, vol. 73, no. 3, pp. 328-335. https://doi.org/10.1002/pros.22573
Algotar, Amit M. ; Stratton, M. Suzanne ; Ahmann, Frederick R ; Ranger-Moore, James ; Nagle, Raymond B ; Thompson, Patricia A. ; Slate, Elizabeth ; Hsu, Chiu-Hsieh ; Dalkin, Bruce L. ; Sindhwani, Puneet ; Holmes, Michael A. ; Tuckey, John A. ; Graham, David L. ; Parnes, Howard L. ; Clark, Lawrence C. ; Stratton, Steven P. / Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. In: Prostate. 2013 ; Vol. 73, No. 3. pp. 328-335.
@article{484aa95ab6874ed4b963b0858c39549b,
title = "Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer",
abstract = "Purpose This study was conducted to investigate the effect of Se supplementation on prostate cancer incidence in men at high risk for prostate cancer. Methods A Phase 3 randomized, double-blind, placebo-controlled clinical trial was conducted in 699 men at high risk for prostate cancer (prostate specific antigen (PSA) >4 ng/ml and/or suspicious digital rectal examination and/or PSA velocity >0.75 ng/ml/year), but with a negative prostate biopsy. Participants were randomized to receive daily oral placebo (N = 232), 200 μg selenium (N = 234), or 400 μg selenium (N = 233) as selenized yeast. They were followed every 6 months for up to 5 years. The time to diagnosis of prostate cancer was compared between treatment groups using the Cox proportional hazards model. Result Compared to placebo, the hazard ratios [95{\%} confidence intervals] for risk of developing prostate cancer in the selenium 200 μg/day or the selenium 400 μg/day group were 0.94 [0.52, 1.7] and 0.90 [0.48, 1.7], respectively. PSA velocity in the selenium arms was not significantly different from that observed in the placebo group (P = 0.18 and P = 0.17, respectively). Conclusion Selenium supplementation appeared to have no effect on the incidence of prostate cancer in men at high risk. In conjunction with Results of other studies, these data indicate that selenium supplementation may not have a role in prostate cancer chemoprevention. Prostate 73: 328-335, 2013. {\circledC} 2012 Wiley Periodicals, Inc.",
keywords = "incidence, prostate cancer, selenium supplementation",
author = "Algotar, {Amit M.} and Stratton, {M. Suzanne} and Ahmann, {Frederick R} and James Ranger-Moore and Nagle, {Raymond B} and Thompson, {Patricia A.} and Elizabeth Slate and Chiu-Hsieh Hsu and Dalkin, {Bruce L.} and Puneet Sindhwani and Holmes, {Michael A.} and Tuckey, {John A.} and Graham, {David L.} and Parnes, {Howard L.} and Clark, {Lawrence C.} and Stratton, {Steven P}",
year = "2013",
month = "2",
day = "15",
doi = "10.1002/pros.22573",
language = "English (US)",
volume = "73",
pages = "328--335",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer

AU - Algotar, Amit M.

AU - Stratton, M. Suzanne

AU - Ahmann, Frederick R

AU - Ranger-Moore, James

AU - Nagle, Raymond B

AU - Thompson, Patricia A.

AU - Slate, Elizabeth

AU - Hsu, Chiu-Hsieh

AU - Dalkin, Bruce L.

AU - Sindhwani, Puneet

AU - Holmes, Michael A.

AU - Tuckey, John A.

AU - Graham, David L.

AU - Parnes, Howard L.

AU - Clark, Lawrence C.

AU - Stratton, Steven P

PY - 2013/2/15

Y1 - 2013/2/15

N2 - Purpose This study was conducted to investigate the effect of Se supplementation on prostate cancer incidence in men at high risk for prostate cancer. Methods A Phase 3 randomized, double-blind, placebo-controlled clinical trial was conducted in 699 men at high risk for prostate cancer (prostate specific antigen (PSA) >4 ng/ml and/or suspicious digital rectal examination and/or PSA velocity >0.75 ng/ml/year), but with a negative prostate biopsy. Participants were randomized to receive daily oral placebo (N = 232), 200 μg selenium (N = 234), or 400 μg selenium (N = 233) as selenized yeast. They were followed every 6 months for up to 5 years. The time to diagnosis of prostate cancer was compared between treatment groups using the Cox proportional hazards model. Result Compared to placebo, the hazard ratios [95% confidence intervals] for risk of developing prostate cancer in the selenium 200 μg/day or the selenium 400 μg/day group were 0.94 [0.52, 1.7] and 0.90 [0.48, 1.7], respectively. PSA velocity in the selenium arms was not significantly different from that observed in the placebo group (P = 0.18 and P = 0.17, respectively). Conclusion Selenium supplementation appeared to have no effect on the incidence of prostate cancer in men at high risk. In conjunction with Results of other studies, these data indicate that selenium supplementation may not have a role in prostate cancer chemoprevention. Prostate 73: 328-335, 2013. © 2012 Wiley Periodicals, Inc.

AB - Purpose This study was conducted to investigate the effect of Se supplementation on prostate cancer incidence in men at high risk for prostate cancer. Methods A Phase 3 randomized, double-blind, placebo-controlled clinical trial was conducted in 699 men at high risk for prostate cancer (prostate specific antigen (PSA) >4 ng/ml and/or suspicious digital rectal examination and/or PSA velocity >0.75 ng/ml/year), but with a negative prostate biopsy. Participants were randomized to receive daily oral placebo (N = 232), 200 μg selenium (N = 234), or 400 μg selenium (N = 233) as selenized yeast. They were followed every 6 months for up to 5 years. The time to diagnosis of prostate cancer was compared between treatment groups using the Cox proportional hazards model. Result Compared to placebo, the hazard ratios [95% confidence intervals] for risk of developing prostate cancer in the selenium 200 μg/day or the selenium 400 μg/day group were 0.94 [0.52, 1.7] and 0.90 [0.48, 1.7], respectively. PSA velocity in the selenium arms was not significantly different from that observed in the placebo group (P = 0.18 and P = 0.17, respectively). Conclusion Selenium supplementation appeared to have no effect on the incidence of prostate cancer in men at high risk. In conjunction with Results of other studies, these data indicate that selenium supplementation may not have a role in prostate cancer chemoprevention. Prostate 73: 328-335, 2013. © 2012 Wiley Periodicals, Inc.

KW - incidence

KW - prostate cancer

KW - selenium supplementation

UR - http://www.scopus.com/inward/record.url?scp=84872799636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872799636&partnerID=8YFLogxK

U2 - 10.1002/pros.22573

DO - 10.1002/pros.22573

M3 - Article

C2 - 22887343

AN - SCOPUS:84872799636

VL - 73

SP - 328

EP - 335

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 3

ER -